New Hydrazinothiazole Derivatives of Usnic Acid as Potent Tdp1 Inhibitors

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Oncology

Background:

• Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a crucial enzyme in DNA repair and a validated target for cancer therapy.
• Combination chemotherapy strategies involving Tdp1 inhibitors may enhance the efficacy of existing chemotherapeutic agents.

Purpose of the Study:

• To synthesize and evaluate novel usnic acid derivatives featuring a hydrazonothiazole pharmacophore as potential Tdp1 inhibitors.
• To assess the synergistic effect of these inhibitors with the chemotherapeutic drug topotecan in cancer treatment.

Main Methods:

• Synthesis of a series of usnic acid derivatives.
• In vitro evaluation of Tdp1 inhibitory activity (IC50 values).
• Binding experiments and molecular modeling to confirm compound activity.
• Assessment of tumor sensitization to topotecan at non-toxic concentrations.

Main Results:

• Several synthesized compounds exhibited potent Tdp1 inhibition with IC50 values in the low nanomolar range.
• Binding studies and molecular modeling corroborated the inhibitory activity.
• The most effective inhibitors sensitized tumors to topotecan at non-toxic concentrations.
• Optimal synergistic effects were observed when Tdp1 inhibitors were administered prior to or simultaneously with topotecan.

Conclusions:

• Novel usnic acid-hydrazonothiazole derivatives are potent Tdp1 inhibitors.
• These compounds can enhance the efficacy of topotecan in cancer therapy, suggesting a promising combination strategy.
• The timing of administration is critical for maximizing the synergistic anticancer effect.